Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 794-799

  Solbeck, Sacha ^a   Meyer, Martin A S ^a   Johansson, Pär I ^a   Meyer, Anna Sina P ^a   Cotton, Bryan A ^b,c   Stensballe, Jakob ^a,d   Schött, Ulf ^e   Ostrowski, Sisse R ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d Rigshospitalet   (Denmark)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Activated recombinant factor VII; Anticoagulation; Atrial fibrillation; Dabigatran; Prothrombin complex concentrate; Thromboelastography

Indexed keywords

ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN;

ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; DRUG MONITORING; FEMALE; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; THROMBOELASTOGRAPHY; YOUNG ADULT;

ADULT; AGED; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; THROMBELASTOGRAPHY; YOUNG ADULT;

EID: 84908214306     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.084     Document Type: Article

References (23)

1. L. Wallentin, S. Yusuf, and M.D. Ezekowitz Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 9745 September 18 2010 975 983
2. T.L. Lindahl, F. Baghaei, and I.F. Blixter Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thromb Haemost 105 2 February 2011 371 378
3. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 6 June 2010 1116 1127
4. T. Baglin, D. Keeling, and S. Kitchen Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology Br J Haematol 159 4 November 2012 427 429
5. F. Schiele, J. van Ryn, and K. Canada A specific antidote for dabigatran: functional and structural characterization Blood 121 18 May 2 2013 3554 3562
6. S. Kaatz, P.A. Kouides, and D.A. Garcia Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors Am J Hematol 87 Suppl. 1 May 2012 S141 S145
7. M. Makris, J.J. van Veen, C.R. Tait, A.D. Mumford, and M. Laffan Guideline on the management of bleeding in patients on antithrombotic agents Br J Haematol 160 1 January 2013 35 46
8. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 14 October 4 2011 1573 1579
9. M. Wolzt, M. Levi, and T.C. Sarich Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers Thromb Haemost 91 6 June 2004 1090 1096
10. P.I. Johansson Goal-directed hemostatic resuscitation for massively bleeding patients: the Copenhagen concept Transfus Apher Sci 43 3 December 2010 401 405
11. J. Stangier, H. Stahle, K. Rathgen, W. Roth, and K. Shakeri-Nejad Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment J Clin Pharmacol 48 12 December 2008 1411 1419
12. P.I. Johansson, M.S. Svendsen, J. Salado, L. Bochsen, and A.T. Kristensen Investigation of the thrombin-generating capacity, evaluated by thrombogram, and clot formation evaluated by thrombelastography of platelets stored in the blood bank for up to 7 days Vox Sang 94 2 February 2008 113 118
13. P.K. Davis, H. Musunuru, M. Walsh, R. Mitra, V. Ploplis, and F.J. Castellino The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine Thromb Haemost 108 3 September 2012 586 588
14. B.A. Cotton, J.J. McCarthy, and J.B. Holcomb Acutely injured patients on dabigatran N Engl J Med 365 21 November 24 2011 2039 2040
15. D.M. Monroe, M. Hoffman, and H.R. Roberts Platelets and thrombin generation Arterioscler Thromb Vasc Biol 22 9 September 1 2002 1381 1389
16. J. Van Ryn Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate D. Ruehl, 2008 [Ref Type: Generic]
17. I. Pragst, S.H. Zeitler, and B. Doerr Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model J Thromb Haemost 10 9 September 2012 1841 1848
18. B. Sorensen, P. Johansen, K. Christiansen, M. Woelke, and J. Ingerslev Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation J Thromb Haemost 1 3 March 2003 551 558
19. M. Takeyama, Y. Sakurai, and M. Shima Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis Blood Coagul Fibrinolysis 18 1 January 2007 1 7
20. B.B. Chesebro, P. Rahn, and M. Carles Increase in activated protein C mediates acute traumatic coagulopathy in mice Shock 32 6 December 2009 659 665
21. C.T. Esmon The protein C pathway Chest 124 3 Suppl September 2003 26S 32S
22. M. Levi, J.H. Levy, H.F. Andersen, and D. Truloff Safety of recombinant activated factor VII in randomized clinical trials N Engl J Med 363 19 November 4 2010 1791 1800
23. U. Schott, and P.I. Johansson Bringing flow into haemostasis diagnostics Br J Anaesth 111 6 2013 864 867